Physicians' Academy for Cardiovascular Education

Heart Failure

Follow the news, literature, and elearning on new developments in the management of Heart Failure.

Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia

Betablocker use associated with reduced mortality in HFrEF patients >80 years

5' education - Oct. 22, 2019 - Paris, France - Gianluigi Savarese, MD

NP metabolism associated with clinical outcomes in HF

5' education - Oct. 15, 2019 - Frank Gommans, MD, PhD

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Cardioprotective mechanisms of SGLT2 inhibitors: What do cardiologists need to know?

10' education - Sep. 24, 2019 - Prof. Nikolaus Marx, MD

Almost significant effects on CV outcomes with ARNI in HFpEF

3' education - Sep. 23, 2019 - Paris, France - Prof. Dirk Jan van Veldhuisen, MD

Early and sustained vasodilation strategy fails to improve outcomes in acute HF

3' education - Sep. 2, 2019 - Prof. Christian Müller

Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes

3' education - Sep. 1, 2019 - Paris, France - Prof. John McMurray

ARNI treatment in HFpEF shows benefit in secondary outcomes, but misses significance in primary endpoint

3' education - Sep. 1, 2019 - Prof. Scott Solomon

Incident hyperkalemia, RAASi use and outcomes in acute hospitalized HF patients

5' education - Aug. 26, 2019 - Joost Beusekamp

A novel parameter for proximal tubular function in HF

5' education - Aug. 21, 2019 - Lisa Emmens

Addressing the risk of hyperkalemia in HF: is there a sweet spot for potassium binding?

10' education - Aug. 21, 2019 - Prof. van der Meer, MD, PhD

Higher dose of loop diuretics limits uptitration RAASi in HFrEF

5' education - Aug. 20, 2019 - Jozine ter Maaten

Understanding and managing obesity-related HFpEF

10' education - July 22, 2019 - Milton Packer, MD

Cardiac amyloidosis: an emerging target in HFpEF?

10' education - July 19, 2019 - Prof. van der Meer, MD, PhD

Heart failure and diabetes: What is the goal of treatment?

10' education - July 17, 2019 - Prof. John McMurray, MD

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD

The future of SGLT2i in HF: Managing patients without T2DM?

10' education - June 20, 2019 - ESC HF 2019 - Prof. Adriaan Voors, MD

Real world practices and outcomes in the management of HF in T2DM patients

10' education - June 20, 2019 - ESC HF 2019 - Prof. Carolyn Lam - Singapore

The essentials about diabetes and heart failure

10' education - June 19, 2019 - ESC HF 2019 - Prof. Martin Cowie - London, UK

Why could patients with HF and T2DM benefit from SGLT2i?

10' education - June 12, 2019 - ESC HF 2019 - Prof. Subodh Verma - Toronto, ON, Canada

ARNI as first-line therapy in de novo HFrEF patients after ADHF event

3' education - June 3, 2019

Potassium binder results in more persistent use of spironolactone in resistant hypertension and CKD, also in a group of HF

3' education - June 3, 2019

Improved QoL with transcatheter mitral valve repair in HF patients with secondary mitral regurgitation

3' education - Apr. 8, 2019

Centrifugal-flow pump superior to axial-flow pump for clinical outcomes in advanced HF

3' education - Apr. 8, 2019

Device safely keeps HF patients out of the hospital

3' education - Mar. 17, 2019

Benefits of early initiation of ARNI in acute HF confirmed in open-label extension study

3' education - Mar. 19, 2019 - Adam DeVore, MD

Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia
Prof. McMurray presents the results of an analysis of DAPA-HF comparing the effect of dapagliflozin in HF patients with and without T2DM.

AHA 2019 Prof. McMurray presents the results of an analysis of DAPA-HF comparing the effect of dapagliflozin in HF patients with and without T2DM.

SGLT2i gives consistent CV benefit in HFrEF patients with or without T2DM

News - Nov. 16, 2019

AHA 2019 This analysis of DAPA-HF shows that dapagliflozin consistently reduced worsening HF events and CV death and improved symptoms in patients with HFrEF, irrespective of diabetes status.

Women more likely to develop acute HF with higher mortality risk after STEMI than men

Literature - Nov. 11, 2019 - Cenko E et al. - J Am Coll Cardiol. 2019

This observational study showed that women had a higher risk to develop acute HF after STEMI and women with acute HF after STEMI had a higher mortality rate compared to men.

SGLT2i approved for treatment of DKD and reduction of HHF in T2DM patients with DKD

News - Oct. 23, 2019

Based on the CREDENCE renal outcomes trial, the FDA granted the approval of canagliflozin to treat diabetic kidney disease (DKD) and reduction of HF hospitalization in patients with T2DM and DKD.

FDA approves SGLT2i for reduction of HF hospitalization in T2DM with high CV risk

News - Oct. 22, 2019

Dapagliflozin is now approved by the FDA to reduce the risk of hospitalization for HF in T2DM patients with high CV risk.

Betablocker use associated with reduced mortality in HFrEF patients >80 years

5' education - Oct. 22, 2019 - Paris, France - Gianluigi Savarese, MD
Gianluigi Savarese tells about his study using data of the SwedeHF registry on the associations between use of betablockers and all-cause and CV mortality in HFrEF patients aged >80 years.

CSI Paris Gianluigi Savarese tells about his study using data of the SwedeHF registry on the associations between use of betablockers and all-cause and CV mortality in HFrEF patients aged >80 years.

NP metabolism associated with clinical outcomes in HF

5' education - Oct. 15, 2019 - Frank Gommans, MD, PhD
Frank Gommans presents a study on the association between levels of corin and neprilysin, enzymes involved in the metabolism of natriuretic peptides, and clinical outcomes in HF patients.

ESC 2019 Frank Gommans presents a study on the association between levels of corin and neprilysin, enzymes involved in the metabolism of natriuretic peptides, and clinical outcomes in HF patients.

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD
Prof. Zannad gives an overview of CV outcome trials with SGLT2 inhibitors; first in diabetes patients and now with results in HF patients in the DAPA-HF trial.

Prof. Zannad gives an overview of CV outcome trials with SGLT2 inhibitors; first in diabetes patients and now with results in HF patients in the DAPA-HF trial.

Identification of determinants of iron deficiency in worsening HF

Literature - Oct. 10, 2019 - Van der Wal H et al., - Eur Heart J 2019

Data of the BIOSTAT-CHF cohort suggest that the etiology of ID in worsening HF is multifactorial and may involve a combination of reduced iron uptake, impaired iron storage and iron loss.

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD
Prof. Verma gives a brief overview on SGLT2i, including data of the DAPA-HF study, potential underlying mechanisms of beneficial CV effects, and recommendations in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD.

ESC 2019 Prof. Verma gives a brief overview on SGLT2i, including data of the DAPA-HF study, potential underlying mechanisms of beneficial CV effects, and recommendations in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD.

ARNI-induced NT-proBNP changes associated with cardiac remodeling changes in HFrEF

Literature - Oct. 2, 2019 - Januzzi JL, et al. - JAMA. 2019

Changes in NT-proBNP with sacubitril/valsartan therapy were correlated with measures of cardiac function and volume in HFrEF patients in the PROVE-HF trial.

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner
Prof. Wanner highlights challenges in patients with CKD and HF, the effect of SGLT2 inhibitors in these patients and future perspectives.

Prof. Wanner highlights challenges in patients with CKD and HF, the effect of SGLT2 inhibitors in these patients and future perspectives.